Compare FRMI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMI | GKOS |
|---|---|---|
| Founded | 2025 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | N/A | 2015 |
| Metric | FRMI | GKOS |
|---|---|---|
| Price | $7.51 | $105.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $29.50 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 6.7M | 557.1K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | $3,427.92 | $27.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $7.17 | $73.16 |
| 52 Week High | $32.39 | $130.23 |
| Indicator | FRMI | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 45.95 |
| Support Level | $7.36 | $104.72 |
| Resistance Level | $10.57 | $113.50 |
| Average True Range (ATR) | 0.59 | 4.04 |
| MACD | -0.10 | 0.15 |
| Stochastic Oscillator | 28.86 | 51.08 |
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.